Treatment type 2 diabetes mellitus patients
A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
1. A method for improving glycemic control in a patient with type 2 diabetes mellitus comprising:
administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical combination comprising lixisenatide and insulin glargine;
wherein the patient has a body mass index (BMI)≥30 kg/m 2 or has experienced a hypoglycemic event;
wherein the patient's type 2 diabetes mellitus is not adequately controlled after treatment with basal insulin; and
wherein the patient requires additional glycemic control without the increase in hypoglycemia and weight gain of prandial insulin.
2. The method of claim 1 , wherein the patient's type 2 diabetes mellitus is not adequately controlled after treatment with basal insulin and metformin.
3. The method of claim 1 , wherein the patient's type 2 diabetes mellitus is not adequately controlled after treatment with basal insulin and one to three oral anti-diabetic drugs (OADs).
4. The method of claim 3 , wherein the one to three OADs are selected from the group consisting of metformin, sulfonylureas, dipeptidyl-peptidase-4 (DPP-4) inhibitors, glinides, or combinations thereof.